Abivax UC maintenance data overblown cancer concern
The market overreacted to perceived cancer signals in Abivax's Phase 3 ulcerative colitis maintenance trial, masking best-in-class efficacy data.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.